Fore Biotherapeutics is a clinical-stage precision oncology company developing targeted therapies for cancers driven by mutations that existing drugs miss. Its lead candidate, plixorafenib (formerly FORE8394), is a next-generation BRAF inhibitor being evaluated in the registration-intended FORTE Phase 2 master protocol, a global basket study across BRAF-altered advanced solid tumors, primary CNS tumors and thyroid cancers. In April 2026 the FDA granted plixorafenib Breakthrough Therapy Designation for adults with BRAF V600E-mutated high-grade glioma. The company runs as a largely virtual organization with its US headquarters at 3675 Market Street in Philadelphia and research ties in Rehovot, Israel.